ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rabeprazole

Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.

Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.

Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 200556 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai210 open or runningphase 3since Sep 12, 2005Aug 19, 2005none ahead
Johnson & Johnsonits history only150 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizerits history only40 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since May 14, 2015Sep 26, 2013none ahead
Viatrisits history only30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Lomond Therapeuticsits history only20 open or runningphase 1since May 1, 2024May 1, 2024none ahead
Torrent Pharmaceuticalsits history only20 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Boehringer Ingelheimits history only10 open or runningphase 1since May 16, 2022May 16, 2022none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 4since May 20, 2013May 20, 2013none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Jun 15, 2015Jun 15, 2015none ahead

Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eisai only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2005First study: phase 2 study in Gastroesophageal RefluxFirst studyNCT00132496 · 111 enrolled · United States
  2. Sep 12, 20052 phase 3 studies in Non-erosive Gastroesophageal Reflux DiseaseNCT00165672, NCT00165646
  3. Sep 13, 2005Phase 2 study in Gastroesophageal RefluxNCT00165841 · 200 enrolled · United States
  4. Oct 10, 20052 phase 3 studies in HeartburnNCT00236197, NCT00236184
  5. Apr 9, 20083 phase 3 studies in Gastroesophageal RefluxNCT00658775, NCT00658632, NCT00658528
  6. Oct 9, 2008Phase 3 study in Esophagitis, PepticNCT00770913 · 337 enrolled · Japan
  7. Feb 5, 20092 phase 3 studies in Gastroesophageal RefluxNCT00839306, NCT00838526
  8. May 29, 2009Phase 3 study in Gastroesophageal RefluxNCT00911534 · 305 enrolled · United States
  9. Mar 11, 20102 phase 1 studies in HealthyNCT01085708, NCT01085695
  10. Mar 17, 2010Phase 2 study in DyspepsiaNCT01089543 · 338 enrolled · Japan
  11. Jun 28, 2010Phase 1 study in HealthyNCT01153659 · 90 enrolled · United States
  12. Sep 14, 2010Phase 2 study in HealthyNCT01202071 · 24 enrolled · Japan
  13. Jul 18, 20112 phase 3 studies in Stomach UlcerNCT01398410, NCT01397448
  14. Mar 24, 2014Phase 3 study in Gastroesophageal RefluxNCT02135107 · 517 enrolled · Japan

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 21 Eisai leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02135107Gastroesophageal Reflux · Japan3CompletedMay 2016517
NCT01398410Stomach Ulcer · Japan3CompletedDec 2013405
NCT01397448Stomach Ulcer · Japan3CompletedMar 2013472
NCT01202071Healthy · Japan2CompletedDec 201024
NCT01153659Healthy · United States1CompletedAug 201090
NCT01089543Dyspepsia · Japan2CompletedAug 2011338
NCT01085708Healthy1CompletedMay 201016
NCT01085695Healthy1CompletedMay 201016
NCT00911534Gastroesophageal Reflux · United States3CompletedJul 2009305
NCT00839306Gastroesophageal Reflux · United States3CompletedAug 2009240
NCT00838526Gastroesophageal Reflux · United States3CompletedJul 31, 2009240
NCT00770913Esophagitis, Peptic · Japan3CompletedNov 2009337
NCT00658775Gastroesophageal Reflux · United States, Argentina, Australia and more3CompletedSep 20091,069
NCT00658632Gastroesophageal Reflux · United States3CompletedApr 20091,397
NCT00658528Gastroesophageal Reflux · United States, Argentina, Australia and more3CompletedSep 20091,061
NCT00236197Heartburn · United States3CompletedMar 2006619
NCT00236184Heartburn · United States3CompletedMar 2006629
NCT00165841Gastroesophageal Reflux · United States2CompletedDec 2005200
NCT00165672Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedOct 200526
NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedOct 2005288
NCT00132496Gastroesophageal Reflux · United States2CompletedMay 2006111

How it is read

Names in the registry

  • “Rabeprazole”, 15 entries
  • “rabeprazole”, 14 entries
  • “rabeprazole sodium”, 10 entries
  • “E3810”, 8 entries
  • “Rabeprazole sodium”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.